Subtopic Deep Dive
Ki67 Expression in Breast Cancer
Research Guide
What is Ki67 Expression in Breast Cancer?
Ki67 expression measures tumor cell proliferation in breast cancer using immunohistochemistry to quantify the percentage of Ki67-positive nuclei as a prognostic marker.
Ki67 serves as a key proliferation index in breast tumors, with higher levels in HER-2 and luminal-B subtypes (Elkablawy et al., 2016, 4393 citations). Meta-analyses confirm its prognostic value in early breast cancer across 12,155 patients (de Azambuja et al., 2007, 944 citations). Recent guidelines standardize Ki67 assessment for improved analytical validity (Nielsen et al., 2020, 660 citations).
Why It Matters
Ki67 guides chemotherapy decisions in hormone receptor-positive breast cancer by identifying high-risk patients needing adjuvant therapy (Aebi et al., 2010). In triple-negative subtypes, elevated Ki67 predicts aggressive behavior and poor response to neoadjuvant chemotherapy (Badve et al., 2010; Wolmark et al., 2001). Population studies link Ki67 levels to recurrence risk, influencing ESMO treatment guidelines (Inwald et al., 2013). These applications impact survival outcomes in over 12,000 patients from meta-analyses (de Azambuja et al., 2007).
Key Research Challenges
Ki67 Assay Standardization
Variability in immunohistochemistry protocols leads to inconsistent Ki67 scores across labs (Nielsen et al., 2020). The International Ki67 Working Group recommends scoring at tumor edges and hotspots for reproducibility. Analytical validity remains limited without unified cut-offs.
Optimal Cut-off Determination
No consensus exists on Ki67 thresholds for risk stratification in luminal cancers (Elkablawy et al., 2016). Meta-analyses show cut-offs vary by subtype, complicating prognostic use (de Azambuja et al., 2007). Population cohorts highlight need for context-specific values (Inwald et al., 2013).
Prognostic Utility in Subtypes
Ki67's value differs across HER-2, luminal-B, and triple-negative breast cancers (Hugh et al., 2009). Challenges arise in integrating Ki67 with multigene assays for DCIS recurrence prediction (Solin et al., 2013). Standardization efforts aim to enhance subtype-specific predictions (Nielsen et al., 2020).
Essential Papers
Ki67 expression in breast cancer
Mohamed A. Elkablawy, Abdulkader M. Albasri, Rabab Mohammed et al. · 2016 · Saudi Medical Journal · 4.4K citations
The Ki67 PI is significantly higher in Saudi BC patients comparing with the reported literature. Ki67 PI was highest in the HER-2 and luminal-B molecular subtypes. Along with other prognostic indic...
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Stefan Aebi, T. Davidson, Günther Gruber et al. · 2010 · Annals of Oncology · 2.9K citations
Preoperative Chemotherapy in Patients With Operable Breast Cancer: Nine-Year Results From National Surgical Adjuvant Breast and Bowel Project B-18
Norman Wolmark, J. Wang, E. Mamounas et al. · 2001 · JNCI Monographs · 1.3K citations
National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-18 was initiated in 1988 to determine whether four cycles of doxorubicin/cyclophosphamide given preoperatively improve surviva...
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients
Evandro de Azambuja, Fátima Cardoso, Gilberto de Castro et al. · 2007 · British Journal of Cancer · 944 citations
Sentinel Lymph Node Biopsy and Axillary Dissection in Breast Cancer: Results in a Large Series
Umberto Veronesi, Giovanni Paganelli, Giuseppe Viale et al. · 1999 · JNCI Journal of the National Cancer Institute · 777 citations
Sentinel lymph node biopsy using a gamma ray-detecting probe allows staging of the axilla with high accuracy in patients with primary breast cancer. A randomized trial is necessary to determine whe...
Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists
Sunil Badve, David J. Dabbs, Stuart J. Schnitt et al. · 2010 · Modern Pathology · 665 citations
Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group
Torsten O. Nielsen, Samuel Leung, David L. Rimm et al. · 2020 · JNCI Journal of the National Cancer Institute · 660 citations
Abstract Ki67 immunohistochemistry (IHC), commonly used as a proliferation marker in breast cancer, has limited value for treatment decisions due to questionable analytical validity. The Internatio...
Reading Guide
Foundational Papers
Start with de Azambuja et al. (2007) for meta-analysis evidence on prognosis in 12,155 patients, then Aebi et al. (2010) ESMO guidelines for clinical integration.
Recent Advances
Nielsen et al. (2020) for updated standardization; Elkablawy et al. (2016) for high-citation subtype data.
Core Methods
IHC on core biopsies with nuclear staining quantification; digital image analysis emerging for reproducibility (Nielsen et al., 2020).
How PapersFlow Helps You Research Ki67 Expression in Breast Cancer
Discover & Search
Research Agent uses searchPapers and exaSearch to find 250M+ papers on Ki67 cut-offs, then citationGraph on Elkablawy et al. (2016) reveals 4393 citing works linking to Saudi cohorts and luminal-B subtypes. findSimilarPapers expands to Nielsen et al. (2020) for standardization guidelines.
Analyze & Verify
Analysis Agent applies readPaperContent to extract Ki67 scoring methods from Nielsen et al. (2020), verifies meta-analysis claims via verifyResponse (CoVe) against de Azambuja et al. (2007), and uses runPythonAnalysis for GRADE grading of proliferation data with statistical tests on cohort sizes.
Synthesize & Write
Synthesis Agent detects gaps in Ki67 subtype integration from Badve et al. (2010), flags contradictions in cut-offs via exportMermaid diagrams. Writing Agent employs latexEditText for methods sections, latexSyncCitations with 10 key papers, and latexCompile for prognostic tables.
Use Cases
"Run statistical analysis on Ki67 proliferation indices from Saudi breast cancer cohorts vs global meta-analyses."
Research Agent → searchPapers('Ki67 Saudi breast cancer') → Analysis Agent → readPaperContent(Elkablawy 2016) + runPythonAnalysis(pandas comparison of PI values vs de Azambuja 2007) → researcher gets matplotlib survival curves and p-values.
"Generate LaTeX review on Ki67 standardization guidelines with citations."
Synthesis Agent → gap detection(Nielsen 2020) → Writing Agent → latexEditText('Ki67 methods') → latexSyncCitations(10 papers) → latexCompile → researcher gets PDF with standardized scoring flowchart.
"Find code for Ki67 image analysis from breast cancer papers."
Research Agent → searchPapers('Ki67 IHC quantification code') → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → researcher gets Python scripts for nuclear counting in QuPath or CellProfiler.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ Ki67 papers: searchPapers → citationGraph → DeepScan 7-step analysis with GRADE checkpoints on Nielsen et al. (2020). Theorizer generates hypotheses on Ki67 cut-offs for triple-negative cancers from Badve et al. (2010) + de Azambuja et al. (2007). DeepScan verifies cohort biases in Elkablawy et al. (2016) via CoVe chains.
Frequently Asked Questions
What is Ki67 expression in breast cancer?
Ki67 is a nuclear protein expressed in proliferating cells, quantified via IHC as percentage of positive tumor nuclei (Nielsen et al., 2020).
What are main methods for Ki67 assessment?
Standardized IHC with manual hotspot counting at 400x magnification, recommended by International Ki67 Working Group (Nielsen et al., 2020).
What are key papers on Ki67 prognosis?
Elkablawy et al. (2016, 4393 citations) on subtype levels; de Azambuja et al. (2007, 944 citations) meta-analysis of 12,155 patients.
What open problems exist in Ki67 research?
Lack of universal cut-offs and assay reproducibility across labs; subtype-specific validation needed (Nielsen et al., 2020; Inwald et al., 2013).
Research Breast Lesions and Carcinomas with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Ki67 Expression in Breast Cancer with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Breast Lesions and Carcinomas Research Guide